Next Steps After a Positive HIV Test
After a positive HIV test, immediate initiation of antiretroviral therapy (ART) is recommended regardless of CD4 count, along with comprehensive laboratory monitoring to characterize HIV stage, general health, and co-infections. 1
Immediate Steps
Confirmation of Diagnosis
- A positive rapid HIV test should be confirmed with Western blot or indirect immunofluorescence assay 1
- While awaiting confirmation, proceed with the following steps without delay 1
Laboratory Evaluation
Before starting ART, obtain the following tests 1:
HIV Stage Assessment:
- HIV RNA level (viral load)
- CD4 cell count
General Health Assessment:
- Kidney function (creatinine)
- Liver function tests
- Lipid levels
- Complete blood count
- Blood glucose level
- Pregnancy test (if applicable)
Co-infection Screening:
- Hepatitis A, B, and C
- Tuberculosis
- Sexually transmitted infections (STIs)
- Serum cryptococcal antigen (if CD4 < 100/μL) 1
Resistance Testing:
- Baseline reverse transcriptase-protease resistance genotype testing 1
Antiretroviral Therapy (ART)
Timing of ART Initiation
- Start ART as soon as possible after diagnosis - ideally same-day or within 7 days 2, 3, 4
- Do not delay ART initiation while waiting for laboratory results unless there is:
- Preexisting kidney or liver damage
- High likelihood of transmitted drug resistance 1
Benefits of Rapid ART Initiation
- Faster viral suppression (48 vs 77 days) 5
- Lower cumulative viral burden 5
- Reduced risk of transmission to others 4
Recommended Initial ART Regimens
- Integrase strand transfer inhibitor (InSTI)-based regimens are preferred:
- Bictegravir plus tenofovir alafenamide/emtricitabine
- Dolutegravir plus tenofovir disoproxil fumarate/emtricitabine
- Dolutegravir plus abacavir/lamivudine 2
Follow-up Monitoring
Early Monitoring
- Assess adherence and medication tolerability within 6 weeks of starting ART 1
- Measure HIV RNA level at this visit 1
- If HIV RNA has not declined considerably within 4-6 weeks despite good adherence, perform genotypic resistance testing 1
Long-term Monitoring
- Monitor HIV RNA every 3 months until viral suppression for at least 1 year 1
- After sustained viral suppression, monitor every 6 months 1
Patient Education and Support
- Explain that HIV is now a manageable chronic disease with near-normal life expectancy when treated 6
- Emphasize the importance of medication adherence
- Discuss that maintaining undetectable viral load means no risk of sexual transmission (U=U: Undetectable = Untransmittable) 2
- Address potential barriers to care (transportation, insurance, housing, stigma) 1
- Consider technology support for medication adherence (alarms, pill boxes, electronic reminders, text messaging) 1
Partner Notification and Prevention
- Discuss disclosure to sexual partners and needle-sharing partners
- Offer PrEP (pre-exposure prophylaxis) to HIV-negative partners 1
- Recommend condoms for all penetrative sexual acts 1
Common Pitfalls to Avoid
Delaying ART initiation - Starting treatment immediately improves outcomes and reduces transmission risk 4
Missing co-infections - Comprehensive screening for hepatitis, tuberculosis, and STIs is essential 1
Inadequate follow-up - Early monitoring of viral load and adherence is critical for successful treatment 1
Overlooking psychosocial support - Address mental health, substance use, and social determinants of health 1
Neglecting resistance testing - Baseline genotype testing is important due to high rates of transmitted drug resistance 1
By following these steps, you can ensure optimal care for patients newly diagnosed with HIV, leading to improved health outcomes and reduced transmission risk.